<DOC>
	<DOCNO>NCT01507831</DOCNO>
	<brief_summary>Alirocumab ( SAR236553/REGN727 ) fully human monoclonal antibody bind PCSK9 ( proprotein convertase subtilisin/kexin type 9 ) . Primary Objective study : To evaluate long-term safety tolerability alirocumab high cardiovascular risk participant hypercholesterolemia adequately control current lipid modifying therapy ( LMT ) . Secondary Objectives : - To evaluate effect alirocumab low-density lipoprotein cholesterol ( LDL-C ) level 24 week treatment comparison placebo . - To evaluate effect alirocumab comparison placebo LDL-C time point . - To evaluate effect alirocumab lipid parameter .</brief_summary>
	<brief_title>Long-term Safety Tolerability Alirocumab ( SAR236553/REGN727 ) Versus Placebo Top Lipid-Modifying Therapy High Cardiovascular Risk Patients With Hypercholesterolemia ( ODYSSEY Long Term )</brief_title>
	<detailed_description>The maximum study duration 89 week per participant , include 3-week screening period , 78-week randomized treatment period 8-week follow-up period .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Either A B adequately control lipidmodifying therapy : A ) Participants heterozygous familial hypercholesterolemia ( heFH ) without establish coronary heart disease ( CHD ) CHD risk equivalent OR B ) Participants hypercholesterolemia together establish CHD CHD risk equivalent . Exclusion criterion : Age &lt; 18 year LDLC &lt; 70 mg/dL ( &lt; 1.81 mmol/L ) Fasting serum triglyceride &gt; 400 mg/dL ( &gt; 4.52 mmol/L ) The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>